Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Survival Outcomes in Patients with Intermediate Risk Acute Myeloid Leukemia: A Single-Center Retrospective Review

Lucia Garcia Mañó, Sandra Pérez, Bernardo López Andrade, MD, Maria Antonia Duran Pastor, Andrés Novo, MD, Antonio Gutiérrez, Antonia Sampol

Blood (2019) 134 (Supplement_1): 5112.

https://doi.org/10.1182/blood-2019-131987

Published: 2019

Journal Articles

RORA Is a Potential Prognostic Biomarker and Therapeutic Target for Patients with Acute Myeloid Leukemia

Christina A. Snider, BA, Kevin Fung, Francesca Gould, Vera Adema, PhD, Cassandra M Kerr, MS, Sunisa Kongkiatkamon, Hassan Awada, MD, Milo Co, Teodora Kuzmanovic, BA, Bhumika J. Patel, MD, Aaron T. Gerds, MD MS, Sudipto Mukherjee, MD PhD MPH, Aziz Nazha, MD, Hetty E. Carraway, MD MBA, Tomas Radivoyevitch, PhD, Jaroslaw P. Maciejewski, MD PhD, Valeria Visconte, PhD, Mikkael A. Sekeres, MD MS, Anjali S. Advani, MD

Blood (2019) 134 (Supplement_1): 2696.

https://doi.org/10.1182/blood-2019-126311

Published: 2019

Journal Articles

Gemtuzumab Ozogamicin in NPM1 -Mutated Acute Myeloid Leukemia (AML): Results from the Prospective Randomized AMLSG 09-09 Phase-III Study

Blood (2018) 132 (Supplement 1): 81.

https://doi.org/10.1182/blood-2018-99-113442

Published: 2018

Journal Articles

High NPM1 -mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML

Sanjay S. Patel, Frank C. Kuo, Christopher J. Gibson, David P. Steensma, Robert J. Soiffer, Edwin P. Alyea, III, Yi-Bin A. Chen, Amir T. Fathi, Timothy A. Graubert, Andrew M. Brunner, Martha Wadleigh, Richard M. Stone, Daniel J. DeAngelo, Valentina Nardi, Robert P. Hasserjian, Olga K. Weinberg

Blood (2018) 131 (25): 2816–2825.

https://doi.org/10.1182/blood-2018-01-828467

Published: 2018

Includes: Supplemental data

Journal Articles

Consensus on MRD in AML?

Elisabeth Paietta

Blood (2018) 131 (12): 1265–1266.

https://doi.org/10.1182/blood-2018-01-828145

Published: 2018

Journal Articles

Early Minimal Residual Disease Assessment after Acute Myeloid Leukemia Induction with Fludarabine Cytarabine and Idarubicin (FLAI) Provides the Most Useful Prognostic Information

Paola Minetto, MD, Fabio Guolo, MD, Marino Clavio, MD, Annalisa Kunkl, MD, Nicoletta Colombo, PhD, Enrico Carminati, Giuseppina Fugazza, Simona Matarese, MD, Daniela Guardo, MD, Filippo Ballerini, MD, Carmen Di Grazia, MD, Anna Maria Raiola, MD, Antonia Cagnetta, MD, Michele Cea, Maurizio Miglino, PhD, Roberto Massimo Lemoli, MD, Marco Gobbi, MD

Blood (2017) 130 (Supplement 1): 5047.

https://doi.org/10.1182/blood.V130.Suppl_1.5047.5047

Published: 2017

Journal Articles

Acute Myeloid Leukemia with Mutated NPM1 Is Dependent on the Cytoplasmic Localization of NPM1c

Lorenzo Brunetti, MD, Michael Gundry, Anna Guzman, Ilaria Gionfriddo, PhD, Federica Mezzasoma, PhD, Francesca Milano, PhD, Maria Paola Martelli, MD PhD, Brunangelo Falini, MD, Margaret Goodell, PhD

Blood (2017) 130 (Supplement 1): 877.

https://doi.org/10.1182/blood.V130.Suppl_1.877.877

Published: 2017

Journal Articles

NPM1 Mutated AML Can Relapse with Wildtype NPM1 and Evolve with Novel Mutations: Implications for Pathobiology and MRD Monitoring

Alexander Höllein, MD, Manja Meggendorfer, PhD, Annette Fasan, PhD, Frank Dicker, PhD, Sabine Jeromin, PhD, Niroshan Nadarajah, Wolfgang Kern, MD, Claudia Haferlach, MD, Torsten Haferlach, MD

Blood (2017) 130 (Supplement 1): 1417.

https://doi.org/10.1182/blood.V130.Suppl_1.1417.1417

Published: 2017

Journal Articles

Deguelin Induced Differentiation of NPM1-Mutant AML In Vivo and in Vitro

Xia Zhang, MD PhD, Zichu Zhao, MD PhD, Sha Yi, MD PhD, Lu Wen, MD PhD, Jing He, MD PhD, Jingyu Hu, MD PhD, Jun Ruan, MD PhD, Jun Fang, MD PhD, Yan Chen, MD PhD

Blood (2016) 128 (22): 4030.

https://doi.org/10.1182/blood.V128.22.4030.4030

Published: 2016

Journal Articles

Mutant nucleophosmin1 (NPM1) Links Protein Translation with Oncogenic Metabolism in Leukemia

Marisa Juntilla, MD PhD, Alina Garbuzov, B.S., Natalie Ortiz, Julia Eberhard, Caitlin Roake, B.S., Yi Yin, B. S., Josh Gruber, MD PhD, Steven Artandi, MD PhD

Blood (2016) 128 (22): 2727.

https://doi.org/10.1182/blood.V128.22.2727.2727

Published: 2016

Journal Articles

HLA Class I-Specific Effects in AML with Mutated Nucleophosmin

Kateřina Kuželová, PhD, Christoph Röllig, MD, Zdenek Racil, MD, Juliane S. Stickel, MD, Barbora Brodská, PhD, Johannes Schetelig, MD MSc, Christian Thiede, MD, Gerhard Ehninger, MD, Grzegorz Helbig, MD PhD, Slawomira Kyrcz-Krzemien, Prof, Jiri Mayer, Petr Cetkovsky, MD MBA, PhD

Blood (2016) 128 (22): 5230.

https://doi.org/10.1182/blood.V128.22.5230.5230

Published: 2016

Journal Articles

RUNX1 Mutation in Cytogenetically Normal Acute Myeloid Leukemia : Clinical Implications, Co-Mutation Analysis

Blood (2016) 128 (22): 5253.

https://doi.org/10.1182/blood.V128.22.5253.5253

Published: 2016

Journal Articles

Immune Response in Acute Myeloid Leukemia with Mutated Nucleophosmin

Katerina Kuzelova, PhD, Barbora Brodská, PhD, Jana Marková, Grzegorz Helbig, MD PhD, Slawomira Kyrcz-Krzemien, MD PhD, Petr Cetkovsky, MD MBA, PhD

Blood (2015) 126 (23): 2572.

https://doi.org/10.1182/blood.V126.23.2572.2572

Published: 2015

Journal Articles

Low-Dose Deguelin, Selective Targeting of Mt NPM1, Induces Differentiation in NPMc+ AML Cells By Regulation the Axis of SIRT1/CEBPβ/G-CSFR, Instead of HDAC1/3

Youping Wang, Zichu Zhao, Jingyu Hu, Fei Zhao, Jing He, Jun Fang, Chun Zhang, Guohui Cui, Yan Chen

Blood (2014) 124 (21): 2231.

https://doi.org/10.1182/blood.V124.21.2231.2231

Published: 2014

Journal Articles

Preclinical Activity of a New Proteasome Inhibitor, MLN9708, in Acute Myelogenous Leukemias Expressing NPM1 Mutated Protein

Jacqueline S Garcia, MD, Min Huang, Bruno C Medeiros, MD, Beverly S. Mitchell, MD

Blood (2014) 124 (21): 993.

https://doi.org/10.1182/blood.V124.21.993.993

Published: 2014

Journal Articles

An Adapted Gating Strategy Integrating a Myelomonocytic Window Is Necessary For Correct Flow Cytometric Diagnosis In a Large Proportion Of AML With Mutated NPM1

Blood (2013) 122 (21): 2593.

https://doi.org/10.1182/blood.V122.21.2593.2593

Published: 2013

Journal Articles

Significance of FAB subclassification of “acute myeloid leukemia, NOS” in the 2008 WHO classification: analysis of 5848 newly diagnosed patients

Roland B. Walter, Megan Othus, Alan K. Burnett, Bob Löwenberg, Hagop M. Kantarjian, Gert J. Ossenkoppele, Robert K. Hills, Kees G. M. van Montfort, Farhad Ravandi, Anna Evans, Sherry R. Pierce, Frederick R. Appelbaum, Elihu H. Estey

Blood (2013) 121 (13): 2424–2431.

https://doi.org/10.1182/blood-2012-10-462440

Published: 2013

Includes: Supplemental data

Journal Articles

Myeloid Sarcoma of the Orbit and Ocular Adnexae

Maro Ohanian, DO, Mona Lisa Alattar, MD, Zeev Estrov, MD, PhD, Alfonso Quintas-Cardama, MD, John T Manning, MD, Farhad Ravandi, MD, Lynne V. Abruzzo, MD, PhD, Jorge E. Cortes, MD, Naveen Pemmaraju, M.D.

Blood (2012) 120 (21): 1463.

https://doi.org/10.1182/blood.V120.21.1463.1463

Published: 2012

Journal Articles

Prognostic Significance of the French-American-British (FAB) Morphologic Subclassification of “Acute Myeloid Leukemia, Not Otherwise Specified” in the 2008 WHO Classification: Analysis of 5,848 Newly Diagnosed Patients From HOVON, MRC/NCRI, SWOG, and MD Anderson Cancer Center

Roland B. Walter, MD, PhD, Megan Othus, PhD, Alan K. Burnett, MD, Bob Löwenberg, MD, PhD, Hagop M. Kantarjian, MD, Gert J. Ossenkoppele, MD, PhD, Robert K. Hills, MA, MSc, DPhil, Kees G.M. van Montfort, PhD, Farhad Ravandi, MD, Anna Evans, PhD, Sherry A. Pierce, RN, BS, Frederick R. Appelbaum, MD, Elihu H. Estey, MD

Blood (2012) 120 (21): 540.

https://doi.org/10.1182/blood.V120.21.540.540

Published: 2012

Journal Articles

Intensive Treatment in Elderly AML Patients Induce Prolonged Survival and Disease Remission If Early Mortality Is Prevented: The Case Record of the San Raffaele Scientific Institute

Massimo Bernardi, MD, Matteo Carrabba, MD, Michela Tassara, MD, Carlo Messina, MD, Alessandro Crotta, MD, Elisa Sala, MD, Alessandro Vignati, Elena Guggiari, MD, Raffaella Greco, MD, Luca vago, MD, Bernhard Gentner, MD, Simona Piemontese, MD, Andrea Assanelli, MD, Jacopo Peccatori, MD, Consuelo Corti, MD, Fabio Ciceri, MD

Blood (2011) 118 (21): 4583.

https://doi.org/10.1182/blood.V118.21.4583.4583

Published: 2011

NARROW

Survival Outcomes in Patients with Intermediate Risk Acute Myeloid Leukemia: A Single-Center Retrospective Review

RORA Is a Potential Prognostic Biomarker and Therapeutic Target for Patients with Acute Myeloid Leukemia

Gemtuzumab Ozogamicin in NPM1 -Mutated Acute Myeloid Leukemia (AML): Results from the Prospective Randomized AMLSG 09-09 Phase-III Study

High NPM1 -mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML

Consensus on MRD in AML?

Early Minimal Residual Disease Assessment after Acute Myeloid Leukemia Induction with Fludarabine Cytarabine and Idarubicin (FLAI) Provides the Most Useful Prognostic Information

Acute Myeloid Leukemia with Mutated NPM1 Is Dependent on the Cytoplasmic Localization of NPM1c

NPM1 Mutated AML Can Relapse with Wildtype NPM1 and Evolve with Novel Mutations: Implications for Pathobiology and MRD Monitoring

Deguelin Induced Differentiation of NPM1-Mutant AML In Vivo and in Vitro

Mutant nucleophosmin1 (NPM1) Links Protein Translation with Oncogenic Metabolism in Leukemia

HLA Class I-Specific Effects in AML with Mutated Nucleophosmin

RUNX1 Mutation in Cytogenetically Normal Acute Myeloid Leukemia : Clinical Implications, Co-Mutation Analysis

Immune Response in Acute Myeloid Leukemia with Mutated Nucleophosmin

Low-Dose Deguelin, Selective Targeting of Mt NPM1, Induces Differentiation in NPMc+ AML Cells By Regulation the Axis of SIRT1/CEBPβ/G-CSFR, Instead of HDAC1/3

Preclinical Activity of a New Proteasome Inhibitor, MLN9708, in Acute Myelogenous Leukemias Expressing NPM1 Mutated Protein

An Adapted Gating Strategy Integrating a Myelomonocytic Window Is Necessary For Correct Flow Cytometric Diagnosis In a Large Proportion Of AML With Mutated NPM1

Significance of FAB subclassification of “acute myeloid leukemia, NOS” in the 2008 WHO classification: analysis of 5848 newly diagnosed patients

Myeloid Sarcoma of the Orbit and Ocular Adnexae

Prognostic Significance of the French-American-British (FAB) Morphologic Subclassification of “Acute Myeloid Leukemia, Not Otherwise Specified” in the 2008 WHO Classification: Analysis of 5,848 Newly Diagnosed Patients From HOVON, MRC/NCRI, SWOG, and MD Anderson Cancer Center

Intensive Treatment in Elderly AML Patients Induce Prolonged Survival and Disease Remission If Early Mortality Is Prevented: The Case Record of the San Raffaele Scientific Institute

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only